Biotechnology revolutionizes the diagnosis and treatment of lymphoma, the seventh most com... 15/09/2024 There are more than 40 types of lymphomas that can generally be grouped into two major subgroups: Hodgkin lymphoma and... AseBio
Biological Sex Differences in Health: Challenges and Opportunities for Personalised Medici... 10/09/2024 Healthcare Personalized medicine Biological sex should be considered as a variable in all health-related biomedical research. Partners - GENESIS Biomed
NLRP3: From Scientific Curiosity to Therapeutic Efficacy 04/09/2024 Healthcare Personalized medicine Advanced therapies Joaquín Gómez Moya, executive president of Viva in Vitro, explains in this forum the important role of the NLRP3... Partners - VIVA IN VITRO
New €1.3 million round for Viva in Vitro brings it over €3 million investment to fight sep... 09/07/2024 Healthcare Personalized medicine In less than 3 years, the Spanish biotech company has attracted the confidence of investors and international medical... Partners - VIVA IN VITRO
Oryzon selected as Associated Partner in the first Important Project of Common European In... 29/05/2024 Healthcare Access to innovation Drug discovery Rare diseases Innovative drugs Personalized medicine Financing Commission has approved up to €1 billion of State aid by six Member States: Belgium, France, Hungary, Italy, Slovakia... Partners - Oryzon Genomics
Atlas Molecular Pharma successfully completes phase one in humans of its treatment for Con... 28/05/2024 Healthcare Access to innovation Drug discovery Rare diseases Innovative drugs Personalized medicine The final results of ATL-001, the biotech company's lead candidate, have shown that it is able to stabilize UROIIIS and... Partners - Inveready
Cellab CDMO obtains a GMP certification for advanced therapy product manufacturing 22/05/2024 Healthcare Access to innovation Personalized medicine Advanced therapies The Spanish Agency for Medicines and Health Products (AEMPS) has certified compliance with the European Union Good... Partners - Cellab
Preclinical studies validate the potential of ApTOLL to reduce inflammation and regenerate... 21/05/2024 Healthcare Access to innovation Innovative drugs Personalized medicine Advanced therapies ApTOLL shows potential for slowing the progression of multiple sclerosis (MS) in preclinical animal studies. Partners - AptaTargets
#NewAseBioMember | “This partnership gives us the possibility to establish key contacts an... 20/05/2024 Healthcare Access to innovation Innovative drugs Personalized medicine Advanced therapies Meet Kirsch Pharma, our new member. We talked to its Raquel Márquez Duro, Key Account Mánager de España y Portugal. AseBio - Kirsch Pharma España
Oryzon reports financial results and corporate update for quarter ended March 31, 2024 07/05/2024 Healthcare Access to innovation Rare diseases Personalized medicine Advanced therapies Financing Finalizing full data analysis from vafidemstat's PORTICO Phase IIb trial in Borderline Personality Disorder (BPD)... Partners - Oryzon Genomics
